Phase I, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM534 Administered Intravenously to Patients With Advanced Solid Tumors
Latest Information Update: 03 May 2023
At a glance
- Drugs PM 534 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors PharmaMar
Most Recent Events
- 17 Jan 2023 New trial record